FDA approves first drug for neurological symptoms in Type 3 Gaucher disease
Adults and children weighing at least 15 kg are eligible for Infilbray. In a 52-week trial, the tablets outperformed enzyme replacement therapy on a combined measure of muscle coordination and thinking.

